ZIOPHARM Oncology Inc (ZIOP) Shares are Up 5.35%

ZIOPHARM Oncology Inc (ZIOP) has been under a strong bear grip, hence the stock is down -17.29% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 4.9% in the past 1 week. The stock has risen by 5.35% in the past week indicating that the buyers are active at lower levels, but the stock is down -15.23% in the past 4 weeks.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.02 and $4.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.12, notching a gain of 2.40% for the day. The total traded volume was 1,224,920 . The stock had closed at $5.00 on the previous day.

The stock has recorded a 20-day Moving Average of 0.52% and the 50-Day Moving Average is 13.26%. ZIOPHARM Oncology, Inc. has dropped 26.86% during the last 3-month period . Year-to-Date the stock performance stands at -38.39%.

ZIOPHARM Oncology Inc (ZIOP) : 2 investment research analysts covering ZIOPHARM Oncology Inc (ZIOP) have an average price target of $14 for the near short term. The highest target price given by the Brokerage Firm to the stock is $21 and the lowest target is $7 for the short term. Analysts expect the variance to be within $9.9 of the average price.


ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *